Nothing Special   »   [go: up one dir, main page]

Qin et al., 2003 - Google Patents

Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studies

Qin et al., 2003

View PDF
Document ID
1345407085856777659
Author
Qin F
Impeduglia T
Schaffer P
Dardik H
Publication year
Publication venue
Journal of vascular surgery

External Links

Snippet

Objective: Deposition of von Willebrand factor (vWF) is increased in hyperplastic intima of grafts, vWF levels are elevated in patients with cardiovascular diseases, and there is resistance to progression of atherosclerosis in pigs with von Willebrand disease. We …
Continue reading at www.sciencedirect.com (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Qin et al. Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studies
Hohenstein et al. Increased mRNA expression of VEGF within the hematoma and imbalance of angiopoietin-1 and-2 mRNA within the neomembranes of chronic subdural hematoma
UA68333C2 (en) Modified factor vii
CA2663547C (en) Method of treating endothelial dysfunction
Mironidou-Tzouveleki et al. Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus
Larsson et al. Valproic acid selectively increases vascular endothelial tissue‐type plasminogen activator production and reduces thrombus formation in the mouse
CN101578376A (en) Methods of diagnosing and treating an inflammatory response
Lundberg et al. Age-related changes in the signaling and function of vascular smooth muscle cells
Wang et al. Myeloid-related protein-14 regulates deep vein thrombosis
Ji et al. C‐reactive protein induces expression of tissue factor and plasminogen activator inhibitor‐1 and promotes fibrin accumulation in vein grafts
Lin et al. Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti‐nonGal IgG binding to porcine aortic endothelial cells
Bustos et al. Platelet-mediated activation of endothelial cells: implications for the pathogenesis of transplant rejection1
Brommer et al. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients
Shin et al. Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis
Stirk et al. Presence of growth-stimulating fibrin degradation products containing fragment E in human atherosclerotic plaques
Omori et al. Inhibition of stromal cell–derived factor-1α/CXCR4 signaling restores the blood-retina barrier in pericyte-deficient mouse retinas
Shepro et al. Plasminogen activator activity by cultured bovine aortic endothelial cells
Chen et al. Recombinant human granulocyte colony-stimulating factor enhanced the resolution of venous thrombi
CN108076629B (en) GM-CSF negative regulator for treating, preventing or improving aortic disease
US8617538B2 (en) Mesodermal-like cell population for treating ischemia in mammals
Nowak et al. Thrombolysis with streptokinase in rabbits dose response, fibrin-clot specificity and laboratory evaluation of fibrinolytic effect
Jiang et al. Tumor necrosis factor-α and the early vein graft
Rabinovitch Pathobiology of pulmonary hypertension: impact on clinical management
Laura et al. Thrombin activated Interleukin-1α drives atherogenesis, but also promotes VSMC proliferation and collagen production.
Li et al. Effects of cinnamic acid on expression of tissue factor induced by TNFα in endothelial cells and its mechanisms